Porphyrins as urokinase-type plasminogen activator receptor antagonists

摘要

The present invention relates to the use of porphyrins as drugs, especially as drugs for urokinase and its receptor (uPAR) mediated diseases. The porphyrines show uPA-uPAR antagonist activity.